Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple Myeloma-Reference-Cited by-同舟云学术

Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple Myeloma

Published:2004-07 Issue:1 Volume:165 Page:71-81
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Inoue Jun,Otsuki Takemi,Hirasawa Akira,Imoto Issei,Matsuo Yoshinobu,Shimizu Shiroh,Taniwaki Masafumi,Inazawa Johji

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference44 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

2. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications;Jelinek;Cancer Res,1993

3. Nonrandom karyotype abnormalities in 36 multiple myeloma patients;Ankathil;Cancer Genet Cytogenet,1995

4. Cytogenetic findings in 200 patients with multiple myeloma;Sawyer;Cancer Genet Cytogenet,1995

5. Multiple myeloma: almost all patients are cytogenetically abnormal;Zandecki;Br J Haematol,1996

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma;Cancers;2024-06-26

2. The numerous facets of 1q21⁺ in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review);Oncology Letters;2024-04-09

3. Approach to High-Risk Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

4. Bispecific Antibodies in the Treatment of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

5. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience;Blood Cancer Journal;2024-01-10